In intensive care units, every minute counts—but the reality is that a limited number of caregivers must rely on their intuition to spot subtle signs of patient deterioration. This often means valuable time is lost before complications are recognized. At the same time, each patient generates thousands of data points every day, creating a wealth of information that could reveal early warning signs. However, most of this data goes unused because existing ICU technologies are not equipped to analyze and interpret these patterns effectively. As a result, critical opportunities to intervene are missed, highlighting the urgent need for smarter solutions that bridge the gap between intuition and data-driven care.

Innocens offers an AI-based early warning app for neonatal sepsis that helps caregivers quickly spot infection signs, improving response times. The system presents patient data as a simple, explainable score and updates continuously. Built on the Intellicens platform, it combines user-friendly design with privacy-focused AI, enabling hospitals to test any prototype AI models at the bedside and supporting healthcare teams advancing their research to real word solutions.

Innocens is a spin-off established by the University Hospital of Antwerp (UZA) and the University of Antwerp (UA), founded by a physician to address the critical issue of neonatal sepsis and reduce infant mortality resulting from this condition.

Innocens is developing a leading ICU platform for preventive, personalized AI-assisted care. Our neonatal sepsis application is being regulated as a medical device in the EU and US. Through select co-development partnerships, we test new AI models with Intellicens software and integrate them into our platform as medical devices.

‍